

Supplementary Information

Asymmetric Three- and [2+1]-Component Conjugate Addition Reactions for the Stereoselective Synthesis of Polysubstituted Piperidinones

Stephen G. Davies,^{*} Paul. M. Roberts and Andrew D. Smith

Department of Organic Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, UK, OX1 3TA

e-mail: steve.davies@chem.ox.ac.uk

Experimental

General Experimental

All reactions involving organometallic or other moisture sensitive reagents were performed under an atmosphere of nitrogen via standard vacuum line techniques. All glassware was flame-dried and allowed to cool under vacuum. THF was distilled under an atmosphere of dry nitrogen from sodium benzophenone ketyl. Water was distilled. *n*-Butyllithium was used as a solution in hexanes at the molarity stated. All other solvents and reagents were used as supplied (Analytical or HPLC grade), without prior purification. Reactions were dried with MgSO₄. Thin layer chromatography (t.l.c.) was performed on aluminium sheets coated with 60 F₂₅₄ silica. Sheets were visualised using iodine, UV light or 1% aqueous KMnO₄ solution. Flash chromatography was performed on Kieselgel 60 silica. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DPX 400 (¹H: 400 MHz and ¹³C: 100.6 MHz) or where stated on a Bruker AMX 500 (¹H: 500 MHz and ¹³C: 125.3 MHz) spectrometer in the deuterated solvent stated. All chemical shifts (δ) are quoted in ppm and coupling constants (*J*) in Hz. Coupling constants are quoted twice, each being recorded as observed in the spectrum without averaging. Residual signals from the solvents were used as an internal reference. ¹³C multiplicities were assigned using a DEPT sequence. In all cases, the reaction diastereoselectivity was assessed by peak integration of the ¹H NMR spectrum of the crude reaction mixture. Infrared spectra were recorded on a Perkin-Elmer 1750 IR Fourier Transform spectrophotometer using either thin films on NaCl plates (film) or KBr discs (KBr) as stated. Only the characteristic peaks are quoted. Low resolution mass spectra (*m/z*) were recorded on VG MassLab 20-250 or Micromass Platform 1 spectrometers

and high resolution mass spectra (HRMS) on a Micromass Autospec 500 OAT spectrometer or on a Waters 2790 Micromass LCT Exact Mass Electrospray Ionisation Mass Spectrometer. Techniques used were chemical ionisation (CI, NH₃), atmospheric pressure chemical ionisation (APCI) or electrospray ionisation (ESI) using partial purification by HPLC with methanol:acetonitrile:water (40:40:20) as eluent. Optical rotations were recorded on a Perkin-Elmer 241 polarimeter with a water-jacketed 10cm cell and are given in units of 10⁻¹ deg cm² g⁻¹. Concentrations are quoted in g/100 ml. Melting points were recorded on a Leica VMTG Galen III apparatus and are uncorrected. Elemental analyses were performed by the microanalysis service of the Inorganic Chemistry Laboratory, Oxford.

Representative Procedure 1

LDA (1M, 1.1eq) was added dropwise to a stirred solution of the requisite β-amino ester (1eq) in anhydrous THF at -78°C under nitrogen and after 10 minutes was allowed to warm to 0°C. After thirty minutes, the enolate solution was recooled to -78°C, prior to the addition of a conjugate acceptor (1eq) in anhydrous THF via cannula. After 15 minutes the solution was warmed to 0°C for two hours before cooling to -78°C and the addition of saturated aqueous ammonium chloride. After warming to rt, the resultant solution was partitioned between brine and 1:1 DCM/Et₂O, the organic extracts were dried, filtered and concentrated *in vacuo* before purification by column chromatography.

Representative Procedure 2

n-Butyllithium (1.55eq) was added dropwise to a stirred solution of (*S*)-*N*-benzyl-*N*-α-methylbenzylamine (1.6eq) in anhydrous THF at -78°C and stirred for thirty minutes under nitrogen. A solution of the α,β-unsaturated ester in anhydrous THF was added dropwise *via* cannula and stirred at -78°C for two hours before the addition of another α,β-unsaturated carbonyl component. After ten minutes, the reaction was warmed to 0°C for two hours before cooling to -78°C and the addition of saturated aqueous ammonium chloride. After warming to rt, the resultant solution was partitioned between brine and 1:1 DCM/Et₂O, and the organic extracts dried, filtered and concentrated *in vacuo* before purification by column chromatography.

Representative Procedure 3

Pd(OH)₂ / C (50% by mass) was added to a solution of the substrate in degassed MeOH and the resultant black suspension stirred under a hydrogen atmosphere (5atm) for 16 hours. After depressurisation, the reaction mixture was filtered through a plug of celite (eluent MeOH), concentrated *in vacuo* and the residue purified by column chromatography on silica gel.

Preparation of 1-*tert*-butyl-5-methyl (2*S*,3*S*,1'*R*, α *S*)-2-{1'-phenyl-(1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-pentanedioate **13** and 1,7-di-*tert*-butyl (2*S*,3*S*,1'*R*, α *S*)-2-{1'-phenyl-(1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-heptanedioate **14**

Following representative procedure 1, LDA (2.0M, 2.64mmol, 1.32ml), **11** (2.4mmol, 1.0g) in THF (5ml) and methyl cinnamate (2.4mmol, 390mg) gave, after column chromatography on silica gel (hexane:Et₂O 15:1 to 10:1), **13** (408mg, 30%) as a mixture of diastereoisomers (66% d.e.). Recrystallisation (hexane:Et₂O) gave **13** as white blocks and as a single diastereoisomer; $[\alpha]_D^{24} +30.4$ (c 1.0, CHCl₃); C₃₈H₄₃NO₄ requires C 79.0; H 7.5; N, 2.4%; found C 78.7; H 7.5; N, 2.3%; $\nu_{\max}$ (KBr) 3027, 2933 (C-H), 1741, 1722 (C=O), 1146 (C-O); δ_H (500MHz, CDCl₃) 1.01 (3H, d, $J_{7,0}$, C(α)Me), 1.26 (9H, s, OC(Me)₃), 2.42 (1H, dd, $J_{4A,4B}$ 16.0, $J_{4A,3}$ 3.4, C(4)*H_A*), 2.94 (1H, dd, $J_{4B,4A}$ 16.0, $J_{4B,3}$ 12.0, C(4)*H_B*), 3.09 (1H, app dt, $J_{3,4B}$ 12.0, $J_{3,4A;3,2}$ 3.5, C(3)*H*), 3.32 (3H, s, CO₂Me), 3.47 (1H, dd, $J_{2,1'}$ 11.9, $J_{2,3}$ 3.9, C(2)*H*), 3.58 (1H, AB, $J_{14,2}$, NCH_A), 4.05 (1H, AB, $J_{14,2}$, NCH_B), 4.21 (1H, q, $J_{7,0}$, C(α)*H*), 4.30 (1H, d, $J_{5,4}$ 11.9, C(1')*H*), 7.05-7.44 (20H, m, *Ph*); δ_C (50MHz, CDCl₃) 16.5 (C(α)Me), 28.0 (OC(Me)₃), 32.4 (C(4)*H₂*), 40.3 (C(3)*H*), 51.1 (NCH₂), 51.3 (OMe), 54.2, 57.2, 62.8 (C(2)*H*, C(1')*H* and C(α)*H*), 80.7 (OC(Me)₃), 126.4, 126.5, 126.7, 127.6, 127.8, 128.2, 128.4, 129.0, 129.6 (*Ph*_{o/m/p}), 136.8, 140.2, 141.7, 144.2 (*Ph*_{ipso}), 171.8, 172.6 (C=O); *m/z* APCI⁺ 578.4, (MH⁺, 75%), 522.1 (MH⁺-C₄H₈, 10%). The mother liquors were further purified by column chromatography to give the minor diastereoisomer of unknown absolute configuration as a white foam (13mg, 1%); $\nu_{\max}$ 3030, 2978 (C-H), 1738, 1721 (C=O), 1151 (C-O); δ_H (300MHz, CDCl₃) 0.84 (9H, s, OC(Me)₃), 0.91 (3H, d, $J_{7,0}$, C(α)Me), 2.01 (1H, dd, $J_{4A,4B}$ 16.6, $J_{4A,3}$ 2.9, C(4)*H_A*), 2.69 (1H, dd, $J_{4B,4A}$ 16.6, $J_{4B,3}$ 12.8, C(4)*H_B*), 3.24 (1H, dd, $J_{2,1'}$ 11.7, $J_{2,3}$ 3.0, C(2)*H*), 3.58 (3H, s, CO₂Me), 3.78 (1H, AB, $J_{13,5}$, NCH_A), 4.00 (1H, d, $J_{11,7}$, C(1')*H*), 4.16-4.25 (2H, m, C(α)*H* and C(3)*H*), 4.30 (1H, AB, $J_{13,5}$, NCH_B), 6.99-7.71 (20H, m, *Ph*); δ_C (50MHz, CDCl₃) 14.0 (C(α)Me), 27.2 (OC(Me)₃), 32.7 (C(4)*H₂*), 38.7

(C(2)H), 50.9 (NCH₂), 51.3, 55.0, 55.2, 59.7 (OMe, C(3)H, C(1')H and C(α)H), 80.2 (OC(Me)₃), 126.5, 126.9, 127.3, 127.7, 127.9, 128.2, 128.4, 128.7, 129.3, 129.8 (*Ph*_{o/m/p}), 139.1, 139.7, 142.7 (*Ph*_{ipso}), 171.3, 173.1 (C=O); *m/z* APCI⁺ 578.4, (MH⁺, 100%), 600.7 (MNa⁺, 10%). Further elution gave **14** (121mg, 15%) as a white foam; C₄₃H₅₁NO₅ requires C, 78.0; H, 7.8; N, 2.1%; found C, 77.7; H, 7.7; N, 2.1%; [α]_D²³ +27.0 (c 1.0, CHCl₃); $\nu_{\max}$ (KBr) 2978 (C-H), 1722 (C=O), 1147 (C-O); δ_{H} (500MHz, CDCl₃) 1.02 (3H, d, *J*_{6,8}, C(α)Me), 1.28 and 1.38 (2 x 9H, s, OC(Me)₃), 2.57 (1H, dd, *J*_{4A,4B}17.2, *J*_{4A,3}2.8, C(4)*H*_A), 2.94 (2H, s, C(6)*H*₂), 3.12-3.16 (1H, m, C(3)*H*), 3.23 (1H, dd, *J*_{4B,4A}17.2, *J*_{4B,3}11.5, C(4)*H*_B), 3.46 (1H, dd, *J*_{2,1'}11.8, *J*_{2,3}3.7, C(2)*H*), 3.60 (1H, AB, *J*_{14,2}, NCH_A), 4.08 (1H, AB, *J*_{14,2}, NCH_B), 4.23 (1H, q, *J*_{6,8}, C(α)*H*), 4.28 (1H, d, *J*_{1',2}11.8, C(1')*H*), 7.02-7.44 (20H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 16.4 (C(α)Me), 27.9, 28.0 (OC(Me)₃ x 2), 39.2 (C(3)H), 41.0, 50.4, 51.1 (C(4)*H*₂, C(6)*H*₂ and NCH₂), 54.2, 57.1, 62.9 (C(2)H, C(1')H, C(α)H), 80.7, 81.5 (2 x OC(Me)₃), 126.5, 126.6, 126.7, 127.7, 127.8, 128.2, 128.3, 128.6, 129.0, 129.7 (*Ph*_{o/m/p}), 136.8, 140.1, 141.7, 144.3 (*Ph*_{ipso}), 166.1, 172.0 (2 x CO₂C(Me)₃), 201.2 (C(5)=O); *m/z* APCI⁺ 662.4 (MH⁺, 100%), 684.0 (MNa⁺, 15%).

X-ray crystal structure determination for **13**

Data were collected using an Enraf-nonius DIP2000 diffractometer with graphite monochromated Mo- α radiation using standard procedures at 100K. The structure was solved by direct methods, full matrix and least-squares refinement with non-hydrogen atoms in anisotropic approximation. Hydrogen atoms were placed in calculated positions and included in the final refinement with fixed positional and thermal parameters. A total of 388 parameters were refined. A three term Chebychev polynomial was used as the weighting scheme. All crystallographic and refinement calculations were carried out using CRYSTALS.³⁵

X-ray crystal structure data for **13** [C₃₈H₄₃NO₄]: *M* = 577.76, orthorhombic, space group P 21 21 21, *a* = 11.2640(2) Å, *b* = 16.6340(3) Å, *c* = 17.0480(2) Å, *V* = 3194.2 Å³, *Z* = 4, μ = 0.07 mm⁻¹, colourless block, crystal dimensions = 0.4 x 0.4 x 0.5 mm³. A total of 3793 unique reflections were measured for 1.81 < 2 θ < 26.78 and 3618 reflections were used in the refinement. The final parameters were *wR*₂ = 0.031 and *R*₁ = 0.025 [*I* > 3 σ (*I*)]. Crystallographic data (excluding structure factors) has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC634494. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].

Preparation of *tert*-butyl (2*S*,3*S*,1'*R*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4'',4''-dimethyl-oxazolidin-2''-one)pentanoate 15

Following representative procedure 1, LDA (2.0M, 1.10mmol, 0.55ml), **11** (1.0mmol, 415mg) in THF (5ml) and *N*-cinnamoyl-4,4-dimethyl-oxazolidin-2-one (0.95mmol, 233mg) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 3:1), **15** (322mg, 49%) as a colourless oil (78% d.e.); Data for major diastereoisomer; $\nu_{\max}$ (film) 3061, 2976 (C-H), 1733, 1717, 1693 (C=O), 1143 (C-O); δ_{H} (500MHz, CDCl₃) 0.72, 0.89 (2 x 3H, s, C(4'')Me₂), 1.13 (3H, d, *J*_{6,8}, C(α)Me), 1.56 (9H, s, OC(Me)₃), 3.00 (2H, ABq, *J*_{8,3}, C(5'')H₂), 3.34 (1H, dd, *J*_{4A,4B}17.3, *J*_{4A,3}4.5, C(4)H_A), 3.54 (1H, app dt, *J*_{3,4B}10.5, *J*_{3,4A;3,2}4.0, C(3)H), 3.60 (1H, AB, *J*_{14,5}, NCH_A), 3.67 (1H, dd, *J*_{2,1'}11.8, *J*_{2,3}3.5, C(2)H), 4.07 (1H, AB, *J*_{14,5}, NCH_B), 4.16 (1H, dd, *J*_{4B,4A}17.3, *J*_{4B,3}10.5, C(4)H_B), 4.30 (1H, q, *J*_{6,8}, C(α)H), 4.80 (1H, d, *J*_{1',2}11.8, C(1')H), 7.02-7.51 (20H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 17.1, 24.1, 24.5 (C(α)Me, C(4'')Me₂), 28.1 (OC(Me)₃), 36.0 (C(4)H₂), 40.6 (C(2)H), 51.2 (NCH₂), 54.7, 58.1, 63.6 (C(3)H, C(1')H and C(α)H), 60.2 (C(4'')Me₂), 75.0 (C(5'')H₂), 80.9 (OC(Me)₃), 126.2, 126.4, 126.5, 127.5, 127.7, 128.1, 128.2, 128.3, 128.9, 129.7 (*Ph*_{o/m/p}), 137.2, 140.5, 142.7, 144.1 (*Ph*_{ipso}), 153.9, 171.8, 172.6 (C=O); *m/z* APCI⁺ 661.6 (MH⁺, 75%), 682.9 (MNa⁺, 10%); HRMS (CI⁺) C₄₂H₄₉N₂O₅ requires 661.3341; found 661.3647.

Preparation of *tert*-butyl (2*S*,3*S*,1'*R*,4''*S*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4''-benzyl-oxazolidin-2''-one)-pentanoate 17

Following representative procedure 1, LDA (2.0M, 1.06mmol, 0.53ml), **11** (0.96mmol, 400mg) in THF (5ml) and (*S*)-*N*-cinnamoyl-4-benzyl-oxazolidin-2-one **16** (0.96mmol, 295mg) in THF (5ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 5:1), **17** (432mg, 62%) as a white foam (86% d.e.); $[\alpha]_{\text{D}}^{22}$ +51.8 (c 1.0, CHCl₃); $\nu_{\max}$ (KBr) 2977 (C-H), 1782, 1718, 1702 (C=O), 1147 (C-O); δ_{H} (500MHz, CDCl₃) 1.06 (3H, d, *J*_{6,8}, C(α)Me), 1.46 (9H, s, OC(Me)₃), 2.37 (1H, dd, *J*_{A,B}13.5, *J*_{A,4''}9.6, C(4'')CH_APh), 2.78 (1H, dd, *J*_{B,A}13.5, *J*_{B,4''}3.1, C(4'')CH_BPh), 2.91 (1H, dd, *J*_{4A,4B}17.4, *J*_{4A,3}4.8, C(4)H_A), 3.26-3.30 (1H, m, C(3)H), 3.52 (1H, dd, *J*_{2,1'}11.8, *J*_{2,3}3.5, C(2)H), 3.57 (1H, AB, *J*_{14,2}, NCH_A), 3.86 (1H, dd, *J*_{4B,4A}17.4, *J*_{4B,3}10.6, C(4)H_B), 4.02-4.10 (2H, m, C(5'')H₂), 4.05 (1H, AB, *J*_{14,2}, NCH_B), 4.20 (1H, q, *J*_{6,8}, C(α)H), 4.36-4.40 (1H, m, C(4'')H), 4.45 (1H, d, *J*_{1',2}11.8, C(1')H), 6.96-7.42 (25H, m, *Ph*); δ_{C} (50MHz,

CDCl₃) 16.9 (C(α)Me), 28.2 (OC(Me)₃), 34.7 (C(4)H₂), 37.4 (C(4'')CH₂Ph), 40.5 (C(2)H), 51.2 (NCH₂), 54.7, 54.9, 57.7, 63.6 (C(3)H, C(1')H, C(4'')H and C(α)H), 65.8 (C(5'')H₂), 81.1 (OC(Me)₃), 126.5, 127.1, 127.7, 127.8, 128.3, 128.4, 128.8, 129.1, 129.4, 129.8 (*Ph*_{o/m/p}), 135.2, 137.4 140.5, 142.9, 144.2 (*Ph*_{ipso}), 153.4, 171.7, 171.9 (C=O); *m/z* APCI⁺ 723.7 (MH⁺, 100%), 745.6 (MNa⁺, 35%); HRMS (CI⁺) C₄₇H₅₁N₂O₅ requires 723.3798; found 723.3794.

Using 1.6eq of enolate; following representative procedure 1, LDA (2.0M, 1.28mmol, 0.64ml, 1.7eq), **11** (1.20mmol, 500mg, 1.6eq) in THF (5ml) and **16** (0.75mmol, 230mg, 1.0eq) in THF (5ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 5:1), **17** as a white foam (449mg, 83%, 86% d.e.).

Preparation of *tert*-butyl (2*S*,3*S*,1'*R*,4''*S*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-(4-methoxyphenyl)-5-oxo-5-(4''-benzyl-oxazolidin-2''-one)-pentanoate **22**

Following representative procedure 1, LDA (2.0M, 1.58mmol, 0.8ml), **11** (1.4mmol, 600mg) in THF (5ml) and (*S*)-*N*-*p*-methoxycinnamoyl-4-benzyl-oxazolidin-2-one **19** (1.4mmol, 486mg) in THF (5ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 8:1 to 5:1) **22** (632mg, 57%) as a white foam (88% d.e.); C₄₈H₅₂N₂O₆ requires C, 76.6; H, 7.0; N, 3.7%; found C, 76.3; H, 7.4; N, 3.7%; [α]_D²² +53.0 (c 1.0, CHCl₃); $\nu_{\max}$ 2970 (C-H), 1777, 1718, 1700 (C=O), 1512 (OMe bend), 1251 (Ph-O), 1147 (C-O); δ_{H} (500MHz, CDCl₃) 1.05 (3H, d, *J*_{6,8}, C(α)Me), 1.48 (9H, s, OC(Me)₃), 2.38 (1H, dd, *J*_{A,B}13.5, *J*_{A,4''}9.4, C(4'')CH_ACH_BPh), 2.79 (1H, dd, *J*_{B,A}13.5, *J*_{B,4''}3.2, C(4'')CH_ACH_BPh), 2.89 (1H, dd, *J*_{4A,4B}17.3, *J*_{4A,3}4.8, C(4)H_A), 3.22 (1H, app dt, *J*_{3,4B}10.5, *J*_{3,2;3,4A}4.2, C(3')H), 3.48 (1H, dd, *J*_{2,1'}11.8, *J*_{2,3}3.5, C(2)H), 3.57 (1H, AB, *J*_{14,3}, NCH_A), 3.75 (3H, s, OMe), 3.81 (1H, dd, *J*_{4A,4B}17.3, *J*_{4B,3}10.5, C(4)H_B), 3.98-4.06 (3H, m, C(5'')H₂ and NCH_B), 4.19 (1H, q, *J*_{6,8}, C(α)H), 4.34-4.39 (1H, m, C(4'')H), 4.43 (1H, d, *J*_{11,8}, C(1')H), 6.75 (2H, m, Ph(3)H and Ph(5)H C₆H₄OMe), 6.94-6.97 (2H, m, *Ph*), 6.99 (2H, m, Ph(2)H and Ph(6)H C₆H₄OMe), 7.15-7.42 (18H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 16.8 (C(α)Me), 28.1 (OC(Me)₃), 34.9 (C(4)H₂), 37.3 (C(4'')CH₂), 39.7 (C(2)H), 51.0 (NCH₂), 54.8, 54.9, 55.1, 57.6, 63.4 (C(3)H, C(1')H, C(4'')H, OMe and C(α)H), 65.7 (C(5'')H₂), 81.0 (OC(Me)₃), 126.4, 127.0, 127.5, 127.7, 128.2, 128.3, 128.6, 128.7, 129.0, 129.3, 129.7 (*Ph*_{o/m/p}), 135.0, 135.1, 137.3, 140.4, 144.1 (*Ph*_{ipso}), 158.0 (*Ph*(4) C₆H₄OMe), 153.2, 171.7, 171.9 (C=O); *m/z* APCI⁺ 774.8 (MH⁺, 100%).

Preparation of *tert*-butyl (2*S*,3*S*,1'*R*,4''*S*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4''-phenyl-oxazolidin-2''-one)-pentanoate **23**

Following representative procedure 1, LDA (2.0M, 2.12mmol, 1.06ml) **11** (1.92mmol, 800mg) in THF (10ml) and (*S*)-*N*-cinnamoyl-4-phenyl-oxazolidin-2-one **20** (2.4mmol, 390mg) in THF (10ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 5:1), **23** (710mg, 52%) as a white foam (92% d.e.); C₄₆H₄₈N₂O₅ requires C, 77.9; H, 6.8; N, 3.95%; found C, 77.95; H, 6.9; N, 3.8%; $\nu_{\max}$ (KBr) 2976 (C-H), 1782, 1719, 1705 (C=O), 1147 (C-O); $[\alpha]_{\text{D}}^{22} +68.0$ (c 1.0, CHCl₃); δ_{H} (500MHz, CDCl₃) 1.05 (3H, d, *J*_{6,8}, C(α)Me), 1.49 (9H, s, OC(Me)₃), 2.89 (1H, dd, *J*_{4A,4B}17.0, *J*_{4A,3}4.9, C(4)*H*_A), 3.19 (1H, app dt, *J*_{3,4B}10.4, *J*_{3,4A;3,2}3.9, C(3)*H*), 3.50 (1H, dd, *J*_{2,1'}11.9, *J*_{2,3}3.1, C(2)*H*), 3.57 (1H, AB, *J*_{14,2}, NCH_A), 3.95 (1H, dd, *J*_{4B,4A}17.0, *J*_{4B,3}10.4, C(4)*H*_B), 4.04 (1H, dd, *J*_{5''A,5''B}8.7, *J*_{5''A,4''}3.9, C(5'')*H*_A), 4.06 (1H, AB, *J*_{14,2}, NCH_B), 4.21 (1H, q, *J*_{6,8}, C(α)*H*), 4.45 (1H, d, *J*_{1',2}11.9, C(1')*H*), 4.51 (1H, t, *J*_{8,7}, C(5'')*H*_B), 5.11 (1H, dd, *J*_{4'',5''B}8.7, *J*_{4'',5''A}3.9, C(4'')*H*), 6.79-7.40 (25H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 16.7 (C(α)Me), 28.2 (OC(Me)₃), 34.4 (C(4)*H*₂), 40.6 (C(2)*H*), 51.1 (NCH₂), 54.6, 57.4, 57.5, 63.4 (C(3)*H*, C(1')*H*, C(4'')*H* and C(α)*H*), 69.7 (C(5'')*H*₂), 81.1 (OC(Me)₃), 125.1, 126.4, 126.5, 127.6, 127.8, 128.0, 128.2, 128.3, 128.8, 129.1, 129.7 (*Ph*_{o/m/p}), 137.2, 138.6, 140.4, 142.5, 144.2 (*Ph*_{ipso}), 153.6, 171.4, 171.9 (C=O); *m/z* APCI⁺ 709.7 (MH⁺, 100%), 731.7 (MNa⁺, 15%), 653.7 (MH⁺-C₄H₈, 5%).

Preparation of *tert*-butyl (2*S*,3*S*,1'*R*,4''*S*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4''-phenyl-5'',5''-dimethyl-oxazolidin-2''-one)-pentanoate **24**

Following representative procedure 1, LDA (2.0M, 1.53mmol, 0.76ml), **11** (1.44mmol, 600mg) in THF (5ml) and (*S*)-*N*-cinnamoyl-4-phenyl-5,5-dimethyloxazolidin-2-one **21** (2.4mmol, 390mg) in THF (5ml) gave, purification by column chromatography on silica gel (hexane:Et₂O 3:1) **24** (502mg, 75%) as a white foam (90% d.e.); $\nu_{\max}$ (KBr) 3028, 2976 (C-H), 1777, 1723 (C=O), 1147 (C-O); $[\alpha]_{\text{D}}^{22} +42.5$ (c 1.0, CHCl₃); δ_{H} (500MHz, CDCl₃) 0.86 (3H, s, C(5'')Me_A), 1.04 (3H, d, *J*_{6,8}, C(α)Me), 1.48 (9H, s, OC(Me)₃), 1.54 (3H, s, C(5'')Me_B), 2.91 (1H, dd, *J*_{4A,4B}17.0, *J*_{4A,3}5.2, C(4)*H*_A), 3.22 (1H, ddd, *J*_{3,4B}10.2, *J*_{3,4A}5.2, *J*_{3,2}3.1, C(3)*H*), 3.44 (1H, dd, *J*_{2,1'}11.9, *J*_{2,3}3.1, C(2)*H*), 3.52 (1H, AB, *J*_{14,3}, NCH_A), 3.90 (1H, dd, *J*_{4B,4A}17.0, *J*_{4B,3}10.3, C(4)*H*_B), 4.01 (1H, AB, *J*_{14,3}, NCH_B), 4.16 (1H, q, *J*_{6,8}, C(α)*H*), 4.46 (1H, d, *J*_{1',2}11.9, C(1')*H*), 4.80 (1H, s,

C(4'')H), 6.68-6.72 (2H, m, *Ph*), 6.99-7.50 (23H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 16.8 (C(α)*Me*), 23.8, 28.8 (C(5'')*Me*₂), 28.2 (OC(*Me*)₃), 34.9 (C(4)H₂), 40.6 (C(2)H), 51.1 (NCH₂), 54.7, 57.7, 63.5, 66.9 (C(3)H, C(1')H, C(4'')H and C(α)H), 81.1, 82.0 (OC(*Me*)₃ and C(5'')*Me*₂), 125.8, 126.4, 127.6, 127.8, 127.9, 128.3, 128.4, 128.5, 129.1, 129.8 (*Ph*_{o/m/p}), 135.9, 137.2, 140.5, 142.9, 144.2 (*Ph*_{ipso}), 153.1, 171.6, 171.9 (C=O); *m/z* APCI⁺ 738.0 (MH⁺, 50%), 681.5 (MH⁺-C₄H₈, 75%); HRMS (CI⁺) C₄₈H₅₃N₂O₅ requires 737.3954; found 737.3943.

Cleavage Reaction to give 1-*tert*-butyl-5-methyl (2*S*,3*S*,1'*R*, α *S*)-2-{1'-phenyl-(1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-pentanedioate 13

To a stirred solution of **24** (100mg, 0.136mmol) in THF (5ml) at -78°C was added a solution of butyllithium (2.5M, 0.338mmol, 2.5eq) in MeOH (1ml) prepared at 0°C. The resultant mixture was stirred at -78°C for ten minutes and then warmed to rt overnight. The reaction was quenched by the addition of pH7 phosphate buffer solution (5ml), partitioned between brine and Et₂O (3 x 80ml), dried and concentrated *in vacuo*. Purification by column chromatography on silica gel (hexane: Et₂O 3:1) gave **13** (76mg, 97%) with identical spectroscopic properties as described earlier. Further elution gave the SuperQuat auxiliary (22mg, 85%).

Cleavage Reaction to give *tert*-butyl (2*S*,3*S*,1'*R*,1''*S*, α *S*)-2-{1'-phenyl-(1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-4-(1''-benzyl-2''-hydroxyethylcarbamoyl)-butanoate 25

To a stirred solution of **17** (200mg, 0.28mmol) in THF (5ml) at -78°C was added a solution of butyllithium (2.5M, 0.69mmol, 2.5eq) in MeOH (2ml) prepared at 0°C. The resultant mixture was stirred at -78°C for ten minutes and then warmed to rt overnight before the addition of pH7 phosphate buffer solution (5ml), the solution partitioned between brine and Et₂O (3 x 80ml), dried and concentrated *in vacuo*. Purification by column chromatography on silica gel (hexane: Et₂O 3:1) gave **13** (46mg, 29%) which was spectroscopically identical to that obtained previously; a more polar fraction yielded **25** (107mg, 56%); ν_{max} (KBr) 3028, 2976 (C-H), 1723, 1654 (C=O), 1147 (C-O); $[\alpha]_{\text{D}}^{22} +18.9$ (c 1.0, CHCl₃); δ_{H} (500MHz, CDCl₃) 1.08 (3H, d, *J*_{6,9}, C(α)*Me*), 1.36 (9H, s, OC(*Me*)₃), 2.38 (1H, dd, *J*_{4A,4B}15.2, *J*_{4A,3}3.9, C(4)*H*_A), 2.49 (1H, dd, *J*_{A,B}13.8, *J*_{6,9}, NCHCH_ACH_BPh), 2.57 (1H, dd, *J*_{B,A}13.8, *J*_{7,3}, NCHCH_ACH_BPh), 2.65 (1H, br s, OH), 2.74 (1H, dd, *J*_{4B,4A}15.2, *J*_{4B,3}11.8, C(4)*H*_B), 3.22 (1H, app dt, *J*_{3,4B}11.8, *J*_{3,4A;3,2}3.7, C(3)*H*), 3.26 (1H, dd, *J*_{A,B}11.0, *J*_{5,0},

NCHCH_ACH_BOH), 3.33 (1H, dd, $J_{B,A}$ 11.0, $J_{3,3}$, NCHCH_ACH_BOH), 3.55 (1H, dd, $J_{2,1'}$ 11.8, $J_{2,3}$ 3.8, C(2)*H*), 3.65 (1H, AB, J 14.2, NCH_A), 3.80-3.84 (1H, m, NCHCH_ACH_B), 4.13 (1H, AB, J 14.2, NCH_B), 4.30 (1H, q, J 6.9, C(α)*H*), 4.38 (1H, d, J 11.8, C(1')*H*), 5.27 (1H, d, J 7.7, NH), 7.03-7.08 (4H, m, *Ph*), 7.20-7.49 (21H, m, *Ph*); δ_C (125MHz, CDCl₃) 16.3 (C(α)*Me*), 27.9 (OC(*Me*)₃), 34.9 (C(4)H₂), 36.4 (NCHCH₂Ph), 41.0 (C(2)*H*), 51.0 (NCH₂), 52.3, 54.0, 57.0, 62.8 (C(3)*H*, C(1')*H*, NCHCH₂Ph and C(α)*H*), 63.4 (NCHCH₂OH), 80.8 (OC(*Me*)₃), 126.3, 126.5, 126.6, 127.6, 127.7, 127.8, 128.1, 128.3, 128.4, 128.9, 129.0, 129.6 (*Ph*_{o/m/p}), 136.7, 137.5, 140.0, 141.5, 144.2 (*Ph*_{ipso}), 171.6, 172.0 (C=O); *m/z* APCI⁺ 697.9 (MH⁺, 100%), 720.0 (MNa⁺, 20%); HRMS (Cl⁺) C₄₆H₅₃N₂O₄ requires 697.4005; found 697.4014.

Preparation of (4*S*,5*S*,6*R*)-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **26** (from **13**)

Following Representative Procedure 3, Pd(OH)₂ on C (60mg) and **13** (120mg, 0.20mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 5:1), **26** as a white solid (56mg, 80%); [α]_D²¹ -17.4 (c 0.65, CHCl₃); ν_{max} (KBr) 3387 (NH), 2978 (C-H), 1711 (C=O_{ester}), 1654 (C=O_{lactam}), 1167 (C-O); δ_H (500MHz, C₆D₆) 0.85 (9H, s, OC(*Me*)₃), 2.57 (1H, dd, $J_{3A,3B}$ 17.3, $J_{3A,4}$ 5.5, C(3)*H*_A), 2.88 (1H, m, C(4)*H*), 2.92 (1H, dd, $J_{5,4}$ 5.5, $J_{5,6}$ 5.0, C(5)*H*), 3.60 (1H, dd, $J_{3B,3A}$ 17.3, $J_{3B,4}$ 13.2, C(3)*H*_B), 4.30 (1H, d, $J_{6,5}$ 5.0, C(6)*H*), 6.92 (1H, br s, NH), 6.98-7.19 (10H, m, *Ph*); δ_C (50MHz, CDCl₃) 27.4 (OC(*Me*)₃), 32.5 (C(3)H₂), 40.9 (C(5)*H*), 51.8 (C(4)*H*), 59.0 (C(6)*H*), 80.7 (OC(*Me*)₃), 126.5, 127.2, 127.3, 128.2, 128.5, 128.6 (*Ph*_{o/m/p}), 138.3, 140.0 (*Ph*_{ipso}), 168.7, 172.6 (C(2) and CO₂C(*Me*)₃); *m/z* APCI⁺ 352.1 (MH⁺, 10%), 374.1 (MNa⁺, 20%), 296.1 (MH⁺-C₄H₈, 100%); HRMS (Cl⁺) C₂₂H₂₆NO₃ requires 352.1920; found 352.1913.

Preparation of (4*S*,5*S*,6*R*)-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **26** (from **17**)

Following Representative Procedure 3, Pd(OH)₂ on C (75mg) and **17** (150mg, 0.21mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 5:1), **25** as a white solid (50mg, 76%) with identical spectroscopic properties to that above.

Preparation of (4*S*,5*S*,6*R*)-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **26** (from **24**)

Following Representative Procedure 3, Pd(OH)₂ on C (75mg) and **24** (200mg, 0.27mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 5:1), **25** as a white solid (80mg, 84%) with identical spectroscopic properties to that previously described.

Preparation of *tert*-butyl (2*R*,3*S*,1'*S*,4''*S*, α *R*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4''-benzyl-oxazolidin-2''-one)-pentanoate **28**

Following Representative Procedure 2, *n*-BuLi (2.5M, 2.47mmol, 0.98ml), (*R*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.36mmol) in THF (5ml), *tert*-butyl cinnamate (438mg, 2.15mmol) in THF (3ml) and (*S*)-4-benzyl-oxazolidin-2-one (660mg, 2.15mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 6:1), **28** (590mg, 38%) as a white foam and as an inseparable mixture of diastereoisomers (85% d.e.), also containing (*S*)-4-benzyl-oxazolidin-2-one (12:1:1); $\nu_{\max}$ (film) 2975 (C-H), 1782, 1728, 1702 (C=O), 1142 (C-O); $[\alpha]_{\text{D}}^{22} +18.3$ (c 1, CHCl₃); δ_{H} (500MHz, CDCl₃) 1.19 (3H, d, *J*_{6,8}, C(α)Me), 1.62 (9H, s, OC(Me)₃), 2.50 (1H, dd, *J*_{A,B}13.5, *J*_{A,4''}9.5, C(4'')CH_ACH_BPh), 2.99 (1H, dd, *J*_{B,A}13.5, *J*_{B,4''}3.2, C(4'')CH_ACH_BPh), 3.31 (1H, dd, *J*_{4A,4B}17.7, *J*_{4A,3}7.3, C(4)*H*_A), 3.38 (1H, dd, *J*_{4B,4A}17.7, *J*_{4B,3'}7.7, C(4)*H*_B), 3.51 (1H, dd, *J*_{2,1'}11.4, *J*_{2,3}5.3, C(2)*H*), 3.53 (1H, d, *J*14.8, NCH_A), 3.52-3.57 (1H, m, C(3)*H*), 3.75 (1H, d, *J*14.8, NCH_B), 4.07 (1H, q, *J*_{6,8}, C(α)*H*), 4.09-4.17 (2H, m, C(5'')H₂), 4.25 (1H, d, *J*11.4, C(1')*H*), 4.53-4.58 (1H, m, C(4'')*H*), 6.81-6.83 (2H, m, *Ph*), 7.06-7.47 (23H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 19.5 (C(α)Me), 28.2 (OC(Me)₃), 37.4, 39.5 (C(4)H₂, C(4'')CH₂Ph), 40.3 (C(2)*H*), 51.4 (NCH₂), 52.4, 55.0, 60.7, 63.9 (C(3)*H*, C(1')*H*, C(4)*H* and C(α)*H*), 66.0 (C(5'')H₂), 81.0 (OC(Me)₃), 126.5, 126.8, 127.3, 127.4, 127.6, 128.0, 128.2, 128.4, 128.5, 128.9, 129.4, 129.5 (*Ph*_{o/m/p}), 135.1, 136.7, 139.2, 141.6, 144.9 (*Ph*_{ipso}), 153.3, 171.3, 171.8 (C=O); *m/z* APCI⁺ 723.8 (MH⁺, 10%), 667.6 (MH⁺-C₄H₈, 30%); HRMS (CI⁺) C₄₇H₅₀N₂O₅Na requires 745.3617; found 745.3669.

Preparation of (4*S*,5*R*,6*S*)-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **29**

Following Representative Procedure 3, Pd(OH)₂ on C (75mg) and **28** (150mg, 0.21mmol, 85% d.e.) in MeOH (5ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 2:1), **29** (50mg, 68%); $\nu_{\max}$ (film) 3424 (NH), 1717 (C=O_{ester}), 1670 (C=O_{lactam}); $[\alpha]_{\text{D}}^{23} +135.7$ (c 1, CHCl₃); δ_{H} (500MHz, C₆D₆) 0.80 (9H, s, OC(Me)₃), 2.25 (1H, dd, *J*_{3A,3B}17.8, *J*_{3A,4}10.9, C(3)*H*_A), 2.76 (1H, dd,

$J_{3B,3A}$ 17.8, $J_{3B,4}$ 5.7, C(3) H_B), 3.05 (1H, dd, $J_{5,4}$ 11.2, $J_{5,6}$ 5.8, C(5) H), 3.15-3.22 (1H, m, C(4) H), 4.51 (1H, dd, $J_{6,5}$ 5.8, $J_{6,NH}$ 3.0, C(6) H), 6.78-7.05 (10H, m, Ph); δ_C (50MHz, $CDCl_3$) 27.2 (OC(Me)₃), 36.6 (C(4) H), 38.6 (C(3) H_2), 51.6 (C(5) H), 56.9 (C(6) H), 81.4 (OC(Me)₃), 127.0, 127.1, 127.6, 128.4, 128.7 ($Ph_{o/m/p}$), 138.7, 142.4 (Ph_{ipso}), 169.1, 171.1 (C(2) and CO₂C(Me)₃); m/z APCI⁺ 352.2 (MH⁺, 20%), 296.2 (MH⁺-C₄H₈, 100%); HRMS (CI⁺) C₂₂H₂₆NO₃ requires 352.1920; found 352.1915.

Preparation of (4*R*,5*S*,6*R*)-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **29**

Following Representative Procedure 3, Pd(OH)₂ on C (50mg) and **31** (100mg) in MeOH (3ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 2:1), **29** (38mg, 80%); $[\alpha]_D^{23}$ -129.4 (c 1, $CHCl_3$).

Preparation of *tert*-butyl (2*S*,3*R*,1'*R*,4''*S*, α *S*)-2-(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-5-oxo-5-(4''-benzyl-oxazolidin-2''-one)-pentanoate **31**

Following Representative Procedure 2, *n*-BuLi (2.5M, 2.47mmol, 0.98ml, 1.15eq), (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.36mmol, 1.1eq) in THF (5ml), *tert*-butyl cinnamate (438mg, 2.15mmol, 1.0eq) in THF (3ml) and (*S*)-4-benzyl-oxazolidin-2-one (660mg, 2.15mmol, 1.0eq) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 6:1), β -amino ester **11** (312mg, 35%) and **31** (434mg, 28%) as a mixture of diastereoisomers (50% d.e.). Repeated chromatographic purification resulted in diastereoisomeric enrichment of the major diastereoisomer (90% d.e.); Data for major diastereoisomer; ν_{max} (KBr) 2974 (C-H), 1783, 1726, 1700 (C=O), 1142 (C-O); δ_H (400MHz, C_6D_6) 1.20 (3H, d, $J_{6,8}$, C(α) Me), 1.69 (9H, s, OC(Me)₃), 2.18 (1H, dd, $J_{A,B}$ 13.2, $J_{A,4''}$ 10.4, C(4'')CH_ACH_BPh), 2.91 (1H, app t, $J_{8,4}$, C(5'')H_A), 3.04 (1H, dd, $J_{B,A}$ 13.2, $J_{B,4''}$ 3.0, C(4'')CH_ACH_BPh), 3.31-3.38 (2H, m, C(4) H_A and C(5'')H_B), 3.54 (1H, AB, $J_{14,4}$, NCH_A), 3.67-3.80 (4H, m, C(4) H_B , C(2) H , C(3) H and NCH_B), 3.84-3.90 (1H, m, C(4'')H), 4.18 (1H, q, $J_{6,8}$, C(α)H), 4.25 (1H, d, $J_{11,7}$, C(1')H), 6.80-6.83 (2H, m, Ph), 6.99-7.34 (23H, m, Ph); δ_C (100MHz, $CDCl_3$) 19.8 (C(α) Me), 28.2 (OC(Me)₃), 37.9, 39.6 (C(4) H_2 , C(4'')CH₂Ph), 51.1 (NCH₂), 40.0, 52.2, 55.2, 61.1, 64.1 (C(3)H, C(2)H, C(1')H, C(4'')H and C(α)H), 66.0 (C(5'')H₂), 80.9 (OC(Me)₃), 126.1, 126.4, 126.7, 127.2, 127.3, 127.5, 127.7, 127.9, 128.1, 128.8, 128.9, 129.4, 130.5

($Ph_{o/m/p}$), 135.4, 136.6, 139.0, 141.5, 145.0 (Ph_{ipso}), 153.2, 171.2, 171.8 (C=O); m/z APCI⁺ 723.4 (MH⁺, 10%), 667.6 (MH⁺-C₄H₈, 30%); HRMS (CI⁺) C₄₇H₅₁N₂O₅ requires 723.3798; found 723.3823.

Preparation of (*E*)-cinnamyl-malonic acid diethyl ester **32**¹

n-Butyllithium (2.5M, 0.91ml, 2.24mmol), was added dropwise to a stirred solution of (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.31mmol) in anhydrous THF (5ml) at -78°C and stirred for thirty minutes under nitrogen. A solution of the dimethyl phenylallylidene malonate in anhydrous THF (5ml) was added dropwise *via* cannula and stirred at -78°C for two hours before the addition of saturated aqueous ammonium chloride. After warming to rt, the resultant solution was partitioned between brine and 1:1 DCM/Et₂O, the organic extracts were dried, filtered and concentrated *in vacuo*. Purification by column chromatography on silica gel (hexane:Et₂O 12:1), **32** (63mg, 16%) as a colourless oil; δ_H (200MHz, CDCl₃) δ_H 1.27 (6H, t, *J*7.1, OCH₂CH₃ x 2), 2.80 (2H, app td, *J*_{3,2}3.4, *J*_{3,5}7.6, C(3)H₂), 3.50 (1H, t, *J*_{2,3}7.6, C(2)H), 4.21 (4H, q, *J*7.1, OCH₂CH₃ x 2), 6.16 (1H, dt, *J*_{4,3}7.6, *J*_{4,5}15.8, C(4)H), 6.49 (1H, br d, *J*_{5,4}15.8, C(5)H), 7.19-7.36 (5H, m, Ph).

Preparation of 1-*tert*-butyl-5-ethyl (2*S*,3*R*,1'*R*, α *S*)-2-[(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-4-ethoxycarbonyl-pentanedioate **34**

Following Representative Procedure 2, *n*-BuLi (2.5M, 2.24mmol, 0.89ml), (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.30mmol) in THF (5ml), *tert*-butyl cinnamate (234mg, 1.15mmol) in THF (3ml) and diethyl benzylidenemalonate (571mg, 2.30mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 6:1) **34** as a hygroscopic white foam (617mg, 81%); ν_{max} (film) 2978 (C-H), 1757, 1732 (C=O), 1141 (C-O); $[\alpha]_D^{24}$ -29.3 (c 1.0, CHCl₃); δ_H (400MHz, CDCl₃) 0.72 (3H, t, *J*7.1, OCH₂CH₃), 1.06 (3H, d, *J*6.8, C(α)Me), 1.25 (3H, t, *J*7.1, OCH₂CH₃), 1.66 (9H, s, CO₂C(Me)₃), 3.32 (1H, dd, *J*_{3,4}12.0, *J*_{3,2}1.0, C(3)H), 3.44 (1H, AB, *J*14.4, NCH_A), 3.55 (1H, dd, *J*_{2,1}12.2, *J*_{2,3}1.0, C(2)H), 3.62-3.66 (3H, m, OCH₂CH₃ and C(4)H), 3.83 (1H, AB, *J*14.4, NCH_B), 4.02 (1H, dq, *J*_{A,B}10.7, *J*_{A,CH3}7.1, OCH_ACH₃), 4.11 (1H, q, *J*6.8, C(α)H), 4.17 (1H, dq, *J*_{B,A}10.7, *J*_{B,CH3}7.1, OCH_BCH₃), 4.72 (1H, d, *J*12.2,

¹ S. Raucher, K-W. Chan and D. S. Jones, *Tetrahedron Lett.*, **1985**, 25, 6261.

C(1')H), 6.94-6.98 (2H, m, *Ph*), 7.14-7.37 (18H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 13.4, 14.1 (OCH₂CH₃), 17.5 (C(α)*Me*), 28.3 (CO₂C(Me)₃), 43.6 (C(3)H), 51.3 (NCH₂), 54.1, 57.0, 58.1 (C(4)H, C(2)H, and C(α)H), 60.9, 61.3 (OCH₂CH₃), 64.1 (C(1')H), 81.2 (CO₂C(Me)₃), 126.2, 126.3, 126.7, 127.3, 127.7, 127.9, 128.3, 128.8, 129.1, 130.5 (*Ph*_{o/m/p}), 137.2, 140.6, 142.4, 144.7 (*Ph*_{ipso}), 167.7, 167.9, 171.9 (CO₂C(Me)₃ and CO₂Et x 2); *m/z* APCI⁺ 664.7 (MH⁺, 100%), 608.3 (MH⁺-C₄H₈, 10%); HRMS (CI⁺) C₄₂H₅₀NO₆ requires 664.3638; found 664.3642.

Preparation of (3*S*,4*R*,5*S*,6*R*)-3-ethoxycarbonyl-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **35**

Following Representative Procedure 3, Pd(OH)₂ on C (75mg), **34** (150mg, 0.23mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (Et₂O:hexane 2:1), **35** (78mg, 81%) as a colourless oil; ν_{max} (film) 3311 (NH), 2977 (C-H), 1723, 1666 (C=O), 1153 (C-O); $[\alpha]_{\text{D}}^{23}$ -72.1 (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 0.92 (9H, s, CO₂C(*Me*)₃), 1.06 (3H, t, *J*_{7,1}, OCH₂CH₃), 3.15 (1H, app t, *J*_{5,4;5,6}4.5, C(5)H), 3.93 (1H, dd, *J*_{4,3}12.7, *J*_{4,5}3.9, C(4)H), 4.03-4.13 (2H, m, OCH₂CH₃), 4.65 (1H, d, *J*_{12,7}, C(3)H), 5.09 (1H, d, *J*_{6,5}5.2, C(6)H), 6.13 (1H, br s, NH), 7.23-7.37 (10H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 13.9 (OCH₂CH₃), 27.4 (CO₂C(*Me*)₃), 44.6, 49.8, 52.0 and 58.8 (C(3)H, C(4)H, C(5)H and C(6)H), 61.3 (OCH₂CH₃), 81.1 (CO₂C(Me)₃), 126.4, 127.6, 127.7, 128.3, 128.6, 128.7 (*Ph*_{o/m/p}), 137.8, 138.1 (*Ph*_{ipso}), 168.8, 170.0 (C(2)=O, CO₂C(Me)₃ and CO₂Et); *m/z* APCI⁺ 424.2 (MH⁺, 5%), 446.0 (MH⁺, 100%), 368.1 (MH⁺-C₄H₈, 20%); HRMS (CI⁺) C₂₅H₃₀NO₅ requires 424.2124; found 424.2126.

Preparation of 1-*tert*-butyl-5-ethyl (2*S*,3*S*,1'*R*, α *S*)-2-[(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-4-ethoxycarbonyl-pentanedioate **36**

Following representative procedure 1, LDA (2.0M, 0.53mmol, 0.27ml), **11** (200mg, 0.48mmol) in THF (5ml) and diethyl benzylidenemalonate (120mg, 0.48mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 10:1), **36** (105mg, 33%) as a colourless oil and as an inseparable 8:1 mixture with diethyl benzylidenemalonate; ν_{max} (film) 2977 (C-H), 1754, 1731(C=O), 1140 (C-O); δ_{H} (400MHz, CDCl₃) 0.68 (3H, t, *J*_{7,3}, OCH₂CH₃), 1.13 (3H, d, *J*_{6,8}, C(α)*Me*), 1.28 (3H, t, *J*_{7,3}, OCH₂CH₃), 1.66 (9H, s, CO₂C(*Me*)₃), 3.42 (1H, AB, *J*_{14,9}, NCH_A), 3.51 (1H, AB, *J*_{14,9}, NCH_B), 3.54-3.61 (2H, m, C(3)H and C(2)H), 3.64-3.69 (2H, m, OCH₂CH₃), 3.89 (1H, d, *J*_{12,2}, C(4)H), 4.06 (1H, d, *J*_{11,5}, C(1')H),

3.98 (1H, q, $J_{6,8}$, C(α)H), 4.14-4.23 (2H, m, OCH₂CH₃), 7.08-7.33 (20H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 13.4, 14.0, 19.9 (OCH₂CH₃ x 2 and C(α)Me), 28.2 (CO₂C(Me)₃), 44.1, 49.4 (C(3)H and C(2)H), 51.2 (NCH₂), 56.1 (C(4)H), 61.1, 61.6 (OCH₂CH₃ x 2), 63.8 (C(1')H), 81.0 (CO₂C(Me)₃), 126.0, 126.3, 127.0, 127.1, 127.2, 127.4, 127.9, 128.0, 128.8, 129.4, 130.2, 130.5 (*Ph*_{o/m/p}), 135.2, 135.7, 141.4, 145.1 (*Ph*_{ipso}), 167.5, 167.8, 171.5 (CO₂C(Me)₃ and CO₂Et x 2); m/z APCI⁺ 664.3 (MH⁺, 100%), 686.6 (MNa⁺, 10%), 608.6 (MH⁺-C₄H₈, 5%); HRMS (CI⁺) C₄₂H₅₀NO₆ requires 664.3638; found 664.3644.

Preparation of (3*S*,4*S*,5*S*,6*R*)-3-ethoxycarbonyl-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **37**

Following Representative Procedure 3, Pd(OH)₂ on C (50mg), **36** (100mg, 0.13mmol) in MeOH (10ml) gave, after purification by column chromatography on silica gel (Et₂O:hexane 2:1), **37** (52mg, 91%) as a colourless oil; ν_{max} (film) 3309 (NH), 2979 (C-H), 1725, 1670 (C=O), 1159 (C-O); $[\alpha]_{\text{D}}^{23}$ -61.8 (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 0.78 (9H, s, CO₂C(Me)₃), 1.09 (3H, t, $J_{7,1}$, OCH₂CH₃), 3.47 (1H, d, $J_{3,4}$ 11.8, C(3)H), 3.54 (1H, dd, $J_{5,4}$ 12.8, $J_{5,6}$ 5.8, C(5)H), 3.78 (1H, app t, $J_{4,3;4,5}$ 12.3, C(4)H), 4.06-4.16 (2H, m, OCH₂CH₃), 5.06 (1H, dd, $J_{6,5}$ 5.8, $J_{6,\text{NH}}$ 3.6, C(6)H), 6.50 (1H, br s, NH), 7.11-7.41 (10H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 13.9 (OCH₂CH₃), 27.0 (CO₂C(Me)₃), 39.3, 50.5, 56.8 and 57.5 (C(3)H, C(4)H, C(5)H and C(6)H), 61.4 (OCH₂CH₃), 81.7 (CO₂C(Me)₃), 127.3, 127.5, 128.1, 128.5, 128.6 (*Ph*_{o/m/p}), 138.0, 139.9 (*Ph*_{ipso}), 167.3, 168.3, 169.2 (C(2)=O, CO₂C(Me)₃ and CO₂Et); m/z APCI⁺ 424.2 (MH⁺, 35%), 446.1 (MNa⁺, 30%), 368.2 (MH⁺-C₄H₈, 100%); HRMS (CI⁺) C₂₅H₃₀NO₅ requires 424.2124; found 424.2127.

Preparation of 1-*tert*-butyl-5-methyl (2*S*,3*R*,1'*R*, α *S*)-2-((1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-(4-bromophenyl)-4-methoxycarbonyl-pentanedioate **38**

Following Representative Procedure 2, *n*-BuLi (2.5M, 2.18mmol, 0.89ml), (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.30mmol) in THF (3ml) and *tert*-butyl cinnamate (234mg, 1.15mmol) in THF (3ml) and dimethyl 4-bromobenzylidenemalonate (515mg, 1.72mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 8:1), **38** (512mg, 63%) as a white foam; ν_{max} (KBr) 2974 (C-H), 1761, 1737 (C=O), 1141 (C-O); $[\alpha]_{\text{D}}^{24}$ -21.6 (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 1.00 (3H, d, $J_{6,8}$, C(α)Me), 1.58 (9H, s, OC(Me)₃), 3.18 (3H, s, CO₂Me), 3.23 (1H, dd, $J_{3,4}$ 11.6, $J_{3,2}$ 1.5, C(3)H), 3.43 (1H, dd, $J_{2,1'}$ 12.2, $J_{2,3}$ 1.5, C(2)H), 3.45 (1H, AB, $J_{14,4}$, NCH_A), 3.57-3.61 (4H, m, CO₂Me and C(4)H), 3.78

(1H, AB, $J_{14.4}$, NCH_B), 4.07 (1H, q, $J_{6.8}$, $C(\alpha)H$), 4.57 (1H, d, $J_{12.2}$, $C(1')H$), 6.73-6.77 (2H, m, Ph), 7.04-7.07 (2H, m, Ph), 7.14-7.34 (15H, m, Ph); δ_C (50MHz, $CDCl_3$) 17.3 ($C(\alpha)Me$), 28.2 ($CO_2C(Me)_3$), 43.1 ($C(2)H$), 51.0 (NCH_2), 52.1, 52.7 ($CO_2Me \times 2$), 53.8, 56.5, 57.9 ($C(3)H$, $C(4)H$, and $C(\alpha)H$), 63.9 ($C(1')H$), 81.6 ($CO_2C(Me)_3$), 120.8 ($Ph(4)$ C_6H_4Br), 126.4, 127.4, 127.7, 128.0, 128.2, 129.1, 130.3, 133.1 ($Ph_{o/m/p}$), 137.1, 140.4, 143.2, 144.6 (Ph_{ipso}), 167.7, 167.9, 171.7 ($CO_2C(Me)_3$ and $CO_2Me \times 2$); m/z APCI⁺ 714 (MH^+ , 100%), 660 ($MH^+ - C_4H_8$, 10%); HRMS (CI^+) $C_{40}H_{45}NBr^{79}O_6$ requires 714.2430, found 714.2444.

Preparation of 1-*tert*-butyl-5-methyl (2*S*,3*R*,1'*R*, α *S*)-2-{(1'-(3,4-dimethoxyphenyl)-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-(4-bromophenyl)-4-methoxycarbonyl-pentanedioate 39

Following Representative Procedure 2, *n*-BuLi (2.5M, 1.47mmol, 0.59ml), (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (321mg, 1.51mmol) in THF (3ml) and *tert*-butyl 3-(3,4-dimethoxyphenyl)-prop-2-enoate (200mg, 0.76mmol) in THF (2ml) and dimethyl 4-bromobenzylidenemalonate (341mg, 1.14mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 8:1), **39** (412mg, 70%) as a white foam; ν_{max} (KBr) 2953 (C-H), 1761, 1737 (C=O), 1141 (C-O); $[\alpha]_D^{24}$ -7.1 (c 1.0, $CHCl_3$); δ_H (400MHz, C_6D_6) 1.17 (3H, d, $J_{6.8}$, $C(\alpha)Me$), 1.54 (9H, s, $OC(Me)_3$), 2.77 (3H, s, CO_2Me), 3.35 (3H, s, OMe), 3.42 (6H, s, CO_2Me and OMe), 3.57 (1H, d, $J_{2,1}$ 12.1, $C(2)H$), 3.64 (1H, AB, $J_{14.8}$, NCH_A), 3.70 (1H, d, $J_{3,4}$ 12.0, $C(3)H$), 3.68 (1H, AB, $J_{14.8}$, NCH_B), 3.99 (1H, d, $J_{4,3}$ 12.0, $C(4)H$), 4.32 (1H, q, $J_{6.8}$, $C(\alpha)H$), 4.92 (1H, d, $J_{1,2}$ 12.1, $C(1')H$), 6.51-6.56 (2H, m, $Ph(2)H$, $Ph(5)H$, $C_6H_3(OMe)_2$), 6.70 (1H, m, $Ph(6)H$ $C_6H_3(OMe)_2$), 6.92- 6.95 (2H, m, Ph), 7.05-7.40 (12H, m, Ph); δ_C (50MHz, $CDCl_3$) 18.1 ($C(\alpha)Me$), 28.3 ($CO_2C(Me)_3$), 43.3 ($C(4)H$), 50.5 (NCH_2), 52.1, 52.6 ($CO_2Me \times 2$), 55.4, 55.8 (OMe), 54.2, 56.6, 59.0 ($C(2)H$, $C(3)H$, and $C(\alpha)H$), 64.3 ($C(1')H$), 81.6 ($CO_2C(Me)_3$), 110.3, 113.2 ($Ph(2)$, $Ph(5)$ $C_6H_3(OMe)_2$), 120.8 ($Ph(4)$ C_6H_4Br), 123.0, 126.4, 126.5, 127.7, 127.9, 128.2, 128.9 ($Ph_{o/m/p}$), 129.4 (Ph_{ipso}), 130.4, 131.0 ($Ph_{o/m/p}$), 140.9, 141.1, 144.5 (Ph_{ipso}), 147.9, 148.1 ($Ph(3)$, $Ph(4)[C_6H_3(OMe)_2]$), 167.8, 167.9, 172.0 ($CO_2C(Me)_3$ and $CO_2Me \times 2$); m/z (ES^+) 774.3 (MH^+ , 80%); HRMS (CI^+) $C_{42}H_{49}N^{79}BrO_8$ requires 774.2642, found 774.2664.

Preparation of 1-*tert*-butyl-5-methyl (2*S*,3*R*,1'*R*, α *S*)-2-{(1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-methyl-4-methoxycarbonyl-pentanedioate 40

Following Representative Procedure 2, *n*-BuLi (1.6M, 2.24mmol, 1.40ml) and (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (500mg, 2.30mmol, 2.0eq) in THF (5ml) and *tert*-butyl cinnamate (234mg, 1.15mmol) in THF (3ml) and dimethyl ethylidenemalonate (273mg, 1.73mmol) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 7:1), **40** (439mg, 67%) as a yellow oil (88%d.e.); $\nu_{\max}$ (film) 2976 (C-H), 1754, 1736 (C=O), 1143 (C-O); $[\alpha]_{\text{D}}^{24} +12.1$ (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 1.01 (3H, d, *J*7.3, C(3)*Me*), 1.07 (3H, d, *J*6.9, C(α)*Me*), 1.53 (9H, s, OC(*Me*)₃), 2.35-2.39 (1H, m, C(3)*H*), 3.18-3.23 (2H, m, C(2)*H* and C(4)*H*), 3.51 (3H, s, CO₂*Me*), 3.55 (1H, AB, *J*14.5, NCH_A), 3.60 (3H, s, CO₂*Me*), 3.89 (1H, AB, *J*14.5, NCH_B), 4.20 (1H, q, *J*6.9, C(α)*H*), 4.38 (1H, d, *J*11.9, C(1')*H*), 7.15-7.39 (15H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 16.0, 17.4 (C(α)*Me* and C(3)*Me*), 28.3 (CO₂C(*Me*)₃), 33.3 (C(3)*H*), 51.0 (NCH₂), 51.9, 52.3, 52.4 (C(2)*H*, CO₂*Me* x 2 and C(4)*H*), 58.1, 62.2 (C(α)*H* and C(1')*H*), 80.8 (CO₂C(*Me*)₃), 126.4, 127.5, 127.8, 128.2, 129.0, 129.7, 130.0 (*Ph*_{o/m/p}), 137.0, 140.5, 144.6 (*Ph*_{ipso}), 168.8, 169.1, 172.0 (CO₂C(*Me*)₃ and CO₂*Me* x 2); *m/z* APCI⁺ 574.3 (MH⁺, 100%), 596.2 (MNa⁺, 20%), 518.2 (MH⁺-C₄H₈, 10%); HRMS (CI⁺) C₃₅H₄₄NO₆ requires 574.3169; found 574.3177.

Preparation of 1-*tert*-butyl-5-ethyl (2*S*,3*R*,1'*R*, α *S*)-2-((1'-phenyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-cinnamyl-4-ethoxycarbonyl-pentanedioate **41 and (*E*)-cinnamyl-malonic acid diethyl ester **32****

Following Representative Procedure 2, *n*-BuLi (2.5M, 1.24mmol, 0.49ml), (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (250mg, 1.18mmol) in THF (5ml) and *tert*-butyl cinnamate (219mg, 1.07mmol) in THF (3ml) and diethyl phenylallylidenemalonate (265mg, 1.07mmol, 1.0eq) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 12:1), (*E*)-cinnamyl-malonic acid diethyl ester **32** as a yellow oil (54mg, 19%) and **41** (472mg, 64%) as a white foam (82% d.e.); Data for major diastereoisomer **41**; $\nu_{\max}$ (KBr) 2976 (C-H), 1751, 1732 (C=O), 1143 (C-O); $[\alpha]_{\text{D}}^{24} +49.3$ (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 0.99 (3H, d, *J*6.8, C(α)*Me*), 1.10-1.16 (2 x 3H, t, *J*7.1, OCH₂CH₃), 1.52 (9H, s, CO₂C(*Me*)₃), 3.02 (1H, m, C(3)*H*), 3.41 (1H, d, *J*_{4,3}6.5, C(4)*H*), 3.51 (1H, dd, *J*_{2,1'}11.4, *J*_{2,3}6.7, C(2)*H*), 3.57 (1H, AB, *J*14.5, NCH_A), 3.95-4.15 (5H, m, OCH₂CH₃ x 2 and NCH_B), 4.22 (1H, q, *J*6.8, C(α)*H*), 4.32 (1H, d, *J*_{1',2}11.4, C(1')*H*), 5.88 (1H, d, *J*15.8, C=CH*Ph*), 5.99 (1H, dd, *J*15.8, *J*9.9, CH=CH*Ph*), 7.00-7.03 (2H, m, *Ph*), 7.12-7.37 (18H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 14.0 (OCH₂CH₃), 17.3 (C(α)*Me*), 28.2 (CO₂C(*Me*)₃), 44.4 (C(3)*H*), 51.1 (NCH₂), 51.8, 54.1, 57.7 (C(2)*H*, C(4)*H* and C(α)*H*), 60.9, 61.2 (OCH₂CH₃ x 2), 63.2 (C(1')*H*), 81.1

(CO₂C(Me)₃), 126.2, 126.3, 126.4, 127.0, 127.3, 127.8, 128.0, 128.1, 128.9, 130.0, 131.4 (*Ph*_{o/m/p}, CH=CHPh), 137.0, 137.5, 140.4, 144.6 (*Ph*_{ipso}), 167.9, 168.0, 172.1 (CO₂C(Me)₃ and CO₂Et x 2); *m/z* APCI⁺ 690.4, (MH⁺, 100%); HRMS (CI⁺) C₄₄H₅₂NO₆ requires 690.3795, found 690.3790.

Preparation of 1-*iso*-propyl-5-ethyl (2*S*,3*R*,1'*S*, α *S*)-2-{(1'-methyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-cinnamyl-4-ethoxycarbonyl-pentanedioate 42

Following Representative Procedure 2, *n*-BuLi (2.5M, 1.21mmol, 0.48ml, 1.15eq) and (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (250mg, 1.18mmol, 1.1eq) in THF (5ml) and *iso*-propyl crotonate (135mg, 1.06mmol, 1.0eq) in THF (3ml) and diethyl phenylallylidene malonate (285mg, 1.06mmol, 1.0eq) in THF (2ml) gave, after purification by column chromatography on silica gel (hexane:Et₂O 10:1) gave a mixture of products. The least polar fraction gave (*E*)-cinnamyl-malonic acid diethyl ester **32** (42mg, 15%) and **42** (404mg, 63%) as a colourless oil (85% d.e.) which was recrystallised (EtOAc:hexane) to give **42** as clear blocks (297mg, 46%); m.p. 121°C (EtOAc:hexane); [α]_D²⁴ +5.0 (c 1.0, CHCl₃); C₃₈H₄₇NO₆ requires C, 74.4; H, 7.7, N, 2.3%; found C, 74.1, H, 7.8, N, 2.15%; $\nu_{\max}$ (KBr) 2970 (C-H), 1748, 1734, 1717 (C=O), 1174 (C-O); δ_{H} (400MHz, CDCl₃) 1.14-1.30 (18H, m, C(α)Me, OCH₂CH₃ x 2, OCH(Me)₂ and C(1')Me), 2.64 (1H, app t, *J*_{2,1';2,3}7.6, C(2)H), 3.08 (1H, ddd, *J*_{3,CH=CHPh}9.9, *J*_{3,2}7.6, *J*_{3,4}5.8, C(3)H), 3.35 (1H, app quin, *J*_{1',Me;1',2}7.0, C(1')H), 3.64 (1H, AB, *J*_{14,4}, NCH_A), 3.75-3.79 (2H, m, NCH_B and C(2)H), 3.98 (1H, q, *J*_{6,9}, C(α)H), 4.03-4.20 (4H, m, OCH₂CH₃ x 2), 4.98 (1H, sept, *J*_{7,2}, OCH(Me)₂), 5.90 (1H, d, *J*_{15,9}, CH=CHPh), 6.26 (1H, dd, *J*_{15,9}, *J*_{9,9}, CH=CHPh), 7.18-7.44 (15H, m, *Ph*); δ_{C} (50MHz, CDCl₃) 13.2, 16.2, 16.6, 21.6, 21.9 (OCH₂CH₃ x 2, C(1')Me, C(α)Me and OCH(Me)₂), 43.3 (C(3)H), 50.1 (NCH₂), 54.2, 54.5, 54.6, 58.7 (C(2)H, C(4)H, C(1')H and C(α)H), 61.0, 61.4 (OCH₂CH₃ x 2), 68.1 (OCH(Me)₂), 126.3, 126.6, 127.4, 127.9, 128.3, 128.4, 128.9 (*Ph*_{o/m/p} and CH=CHPh), 137.1 (CH=CHPh), 141.0, 144.0, 144.6 (*Ph*_{ipso}), 168.1, 168.6, 172.6 (CO₂CH(Me)₂ and CO₂Et x 2); *m/z* APCI⁺ 614.4 (MH⁺, 100%), 636.1 (MNa⁺, 10%).

Preparation of 1-*iso*-propyl-5-ethyl (2*S*,3*R*,1'*S*, α *S*)-2-{(1'-methyl-1'-*N*-benzyl-*N*- α -methylbenzylamino)-3-phenyl-4-ethoxycarbonyl-pentanedioate 43

Following Representative Procedure 2, *n*-BuLi (2.5M, 1.21mmol, 0.48ml, 1.15eq) and (*S*)-*N*-benzyl-*N*- α -methylbenzylamine (250mg, 1.18mmol, 1.1eq) in THF (5ml) and *iso*-propyl crotonate (135mg, 1.06mmol,

1.0eq) in THF (3ml) and diethyl benzylidenemalonate (261mg, 1.06mmol, 1.0eq) in THF (2ml), gave after purification by column chromatography on silica gel (hexane:Et₂O 10:1), **43** (324mg, 52%) as a yellow oil (78% d.e.), which crystallised on standing to give **43** as clear blocks (230mg, 37%); m.p. 59°C; $\nu_{\max}$ (KBr) 2980 (C-H), 1755, 1731 (C=O), 1171 (C-O); $[\alpha]_{\text{D}}^{23} +42.0$ (c 0.25, CHCl₃); δ_{H} (400MHz, CDCl₃) 0.93 (3H, t, $J_{7,1} 7.1$, OCH₂CH₃), 1.08 (3H, d, $J_{6,8} 6.8$, C(1')Me), 1.21-1.29 (12H, m, C(α)Me, OCH₂CH₃ and OCH(Me)₂), 2.90 (1H, dd, $J_{2,1} 9.2$, $J_{2,3} 5.5$, C(2)H), 3.43 (1H, dq, $J_{1',2} 9.2$, $J_{1',\text{Me}} 6.8$, C(1')H), 3.63 (2H, m, NCH₂), 3.68 (1H, dd, $J_{3,4} 9.4$, $J_{3,2} 5.5$, C(3)H), 3.80-3.88 (2H, m, OCH₂CH₃), 3.90 (1H, q, $J_{6,9} 6.9$, C(α)H), 3.97 (1H, d, $J_{4,3} 9.4$, C(4)H), 4.01-4.15 (2H, m, OCH₂CH₃), 4.99 (1H, sept, $J_{6,2} 6.2$, OCH(Me)₂), 7.04-7.37 (15H, m, Ph); δ_{C} (50MHz, CDCl₃) 13.6, 13.9, 15.4, 17.4, 21.7, 22.0 (OCH₂CH₃ x 2, C(1')Me, C(α)Me and OCH(Me)₂), 43.7 (C(3)H), 49.6 (NCH₂), 55.3, 55.6, 56.7, 59.5 (C(2)H, C(4)H, C(1')H and C(α)H), 61.0, 61.4 (OCH₂CH₃ x 2), 68.2 (OCH(Me)₂), 126.4, 126.5, 126.8, 127.8, 128.0, 128.8, 129.0 ($Ph_{\text{o/m/p}}$), 140.9, 141.2, 143.7 (Ph_{ipso}), 168.0, 168.3, 172.7 (CO₂CH(Me)₂ and CO₂Et x 2); m/z APCI⁺ 588.3, (MH⁺, 100%), 610.3 (MNa⁺, 5%); HRMS (CI⁺) C₃₆H₄₆NO₆ requires 588.3325, found 588.3320.

Preparation of (3*S*,4*R*,5*S*,6*R*)-3-methoxycarbonyl-4,6-diphenyl-5-*tert*-butoxycarbonyl-piperidin-2-one **44**

Following Representative Procedure 3, Pd(OH)₂ on C (75mg), **38** (150mg, 0.21mmol) in MeOH (5ml), gave, after purification by column chromatography on silica gel (Et₂O:hexane 2:1), **44** as an off white solid (78mg, 90%); $\nu_{\max}$ (KBr) 3436 (NH), 2922 (C-H), 1724, 1661 (C=O), 1154 (C-O); $[\alpha]_{\text{D}}^{24} -69.2$ (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 0.91 (9H, s, CO₂C(Me)₃), 3.15 (1H, app t, $J_{5,4;5,6} 4.5$, C(5)H), 3.62 (3H, s, CO₂Me), 3.95 (1H, dd, $J_{4,3} 12.7$, $J_{4,5} 3.9$, C(4)H), 4.66 (1H, d, $J_{3,4} 12.7$, C(3)H), 5.09 (1H, d, $J_{6,5} 5.1$, C(6)H), 6.28 (1H, br s, NH), 7.23-7.39 (10H, m, Ph); δ_{C} (100MHz, CDCl₃) 27.4 (CO₂C(Me)₃), 44.4, 49.7, 52.1, 52.5 and 58.7 (C(3)H, C(4)H, C(5)H, C(6)H and CO₂Me), 81.2 (CO₂C(Me)₃), 126.4, 127.4, 127.7, 128.4, 128.6, 128.7 ($Ph_{\text{o/m/p}}$), 137.7, 138.1 (Ph_{ipso}), 168.6, 168.8, 170.5 (C(2), CO₂C(Me)₃ and CO₂Me); m/z APCI⁺ 410.2 (MH⁺, 100%), 432.2 (MH⁺, 40%), 354.2 (MH⁺-C₄H₈, 50%); HRMS (CI⁺) C₂₄H₂₈NO₅ requires 410.196748; found 410.197534.

Preparation of (3*S*,4*R*,5*S*,6*R*)-3-methoxycarbonyl-4-methyl-5-*tert*-butoxycarbonyl-6-phenyl-piperidin-2-one **45**

Following Representative Procedure 3, Pd(OH)₂ on C (75mg) and **40** (150mg, 0.26mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (Et₂O:hexane 2:1), **45** as a colourless oil (70mg, 78%); $\nu_{\max}$ (film) 3421 (NH), 1741, 1717 (C=O_{ester}), 1654 (C=O_{lactam}), 1155 (C-O); $[\alpha]_{\text{D}}^{23} +1.9$ (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 1.08 (3H, d, $J_{6,8}$, C(4)*Me*), 1.15 (9H, s, CO₂C(*Me*)₃), 2.75 (1H, dqd, $J_{4,3}$ 11.9, $J_{4,\text{Me}}$ 6.8, $J_{4,5}$ 4.4, C(4)*H*), 2.94 (1H, app t, $J_{5,4;5,6}$ 4.5, C(5)*H*), 3.73 (1H, d, $J_{3,4}$ 11.9, C(3)*H*), 3.80 (3H, s, CO₂*Me*), 4.90 (1H, d, $J_{6,5}$ 5.0, C(6)*H*), 6.22 (1H, br s, NH), 7.09-7.38 (5H, m, *Ph*); δ_{C} (100MHz, CDCl₃) 17.7 (C(4)*Me*), 27.7 (CO₂C(*Me*)₃), 33.8 (C(4)*H*), 51.2 (C(5)*H*), 52.6 and 52.7 (C(3)*H* and CO₂*Me*), 58.1 (C(6)*H*), 81.5 (CO₂C(*Me*)₃), 126.3, 128.4, 128.7 (*Ph*_{o/m/p}), 137.9 (*Ph*_{ipso}), 168.5, 168.9, 171.2 (C(2), CO₂C(*Me*)₃ and CO₂*Me*); m/z APCI⁺ 348.2 (MH⁺, 30%), 370.1 (MNa⁺, 50%), 292.2 (MH⁺-C₄H₈, 100%); HRMS (CI⁺) C₁₉H₂₆NO₅ requires 348.1811; found 348.1813.

Preparation of (3*S*,4*R*,5*S*,6*R*)-3-ethoxycarbonyl-4-hydrocinnamyl-5-*tert*-butoxycarbonyl-6-phenyl-piperidin-2-one **46**

Following Representative Procedure 3, Pd(OH)₂ on C (50mg), **41** (100mg, 0.14mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (hexane:EtOAc 5:1), **46** as an off white solid (52mg, 80%); $\nu_{\max}$ (KBr) 3343 (NH), 2977 (C-H), 1726 (C=O_{ester}), 1678 (C=O_{lactam}), 1150 (C-O); $[\alpha]_{\text{D}}^{24} -17.0$ (c 1.0, CHCl₃); δ_{H} (400MHz, CDCl₃) 1.19 (9H, s, CO₂C(*Me*)₃), 1.29 (3H, t, $J_{7,1}$, OCH₂CH₃), 1.59-1.65, 1.74-1.79 (2 x 1H, m, PhCH₂CH₂), 2.58-2.71 (2H, m, C(4)*H* and PhCH_ACH_B), 2.82-2.88 (1H, m, PhCH_ACH_B), 3.16 (1H, app t, $J_{4,4}$, C(5)*H*), 3.73 (1H, d, $J_{1,1.8}$, C(3)*H*), 4.25 (2H, q, $J_{7,1}$, OCH₂CH₃), 4.85 (1H, d, $J_{4,8}$, C(6)*H*), 6.04 (1H, br s, NH), 7.14-7.41 (10H, m, *Ph*); δ_{C} (100MHz, CDCl₃) 14.1 (OCH₂CH₃), 27.8 (CO₂C(*Me*)₃), 32.8, 34.1 (PhCH₂CH₂), 38.5 (C(4)*H*), 48.1 (C(5)*H*), 52.4 (C(3)*H*), 58.2 (C(6)*H*), 61.6 (OCH₂CH₃), 81.6 (CO₂C(*Me*)₃), 126.2, 126.4, 128.1, 128.5, 128.6, 128.8 (*Ph*_{o/m/p}), 138.1, 141.0 (*Ph*_{ipso}), 168.4, 168.8, 170.8 (C(2), CO₂C(*Me*)₃ and CO₂Et); m/z APCI⁺ 452.0 (MH⁺, 30%), 474.2 (MNa⁺, 25%), 396.2 (MH⁺-C₄H₈, 100%); HRMS (CI⁺) C₂₇H₃₄NO₅ requires 452.2437, found 452.2441.

Preparation of (3*S*,4*R*,5*S*,6*S*)-3-ethoxycarbonyl-4-hydrocinnamyl-5-*iso*-propoxycarbonyl-6-methyl-piperidin-2-one **47**

Following Representative Procedure 4, Pd(OH)₂ on C (50mg) and **42** (100mg, 0.16mmol) in MeOH (5ml) gave, after purification by column chromatography on silica gel (Et₂O:hexane 2:1), **47** as a colourless oil (46mg, 75%); R_f (0.20); [α]_D²³ -78.4 (c 1.0, CHCl₃); ν_{max} (KBr) 3205 (NH), 2980 (C-H), 1728 (C=O_{ester}), 1661 (C=O_{lactam}), 1186 (C-O); δ_H (400MHz, CDCl₃) 1.23-1.28 (12H, m, OCH₂CH₃, OCH(Me)₂ and C(6)H₃), 1.54-1.65 (1H, m, C(4)CH_A), 1.68-1.77 (1H, m, C(4)CH_B), 2.44-2.51 (1H, m, C(4)H), 2.53-2.60 (1H, m, C(4)CH₂CH_A), 2.77-2.84 (1H, m, C(4)CH₂CH_B), 2.93 (1H, app t, *J*_{5,4;5,6} 4.0, C(5)H), 3.51 (1H, d, *J* 11.4, C(3)H), 3.75-3.81 (1H, m, C(6)H), 4.21 (2H, q, OCH₂CH₃), 5.11 (1H, sept, *J* 6.2, OCH(Me)₂), 6.48 (1H, br s, NH), 7.12-7.30 (5H, m, *Ph*); δ_C (100MHz, CDCl₃) 14.1, 19.1, 21.9, 22.0 (OCH₂CH₃, C(6)H₃ and OCH(Me)₂), 32.8, 34.2 (C(4)CH₂CH₂Ph), 38.3, 45.9, 49.3, 52.5 (C(3)H, C(4)H, C(5)H, C(6)H), 61.5 (OCH₂CH₃), 68.5 (OCH(Me)₂), 126.1, 128.1, 128.5 (*Ph*_{o/m/p}), 141.0 (*Ph*_{ipso}), 168.0, 169.7, 170.9 (C(2), CO₂CH(Me)₂ and CO₂Et); *m/z* APCI⁺ 376.2 (MH⁺, 100%), 398.1 (MNa⁺, 40%), 354.2 (MH⁺-C₄H₈, 50%); HRMS (CI⁺) C₂₁H₃₀NO₅ requires 376.2124; found 376.2125.